ImmuCell (NASDAQ:ICCC) Shares Pass Below 200 Day Moving Average of $5.12

Shares of ImmuCell Co. (NASDAQ:ICCC) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.12 and traded as low as $4.56. ImmuCell shares last traded at $4.62, with a volume of 22,230 shares trading hands.

ImmuCell Price Performance

The stock’s fifty day simple moving average is $5.10 and its 200-day simple moving average is $5.12. The company has a market capitalization of $35.79 million, a P/E ratio of -5.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.59 and a quick ratio of 0.81.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.12) EPS for the quarter. The company had revenue of $5.40 million for the quarter. ImmuCell had a negative net margin of 38.70% and a negative return on equity of 22.63%.

Hedge Funds Weigh In On ImmuCell

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its stake in shares of ImmuCell by 7.4% during the third quarter. Dimensional Fund Advisors LP now owns 22,579 shares of the biotechnology company’s stock worth $169,000 after buying an additional 1,563 shares during the last quarter. Morgan Stanley lifted its holdings in ImmuCell by 3.8% in the fourth quarter. Morgan Stanley now owns 76,874 shares of the biotechnology company’s stock valued at $469,000 after buying an additional 2,800 shares during the period. HM Payson & Co. raised its holdings in shares of ImmuCell by 49.2% during the second quarter. HM Payson & Co. now owns 12,130 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 4,000 shares during the period. Cresset Asset Management LLC raised its holdings in shares of ImmuCell by 4.2% in the 1st quarter. Cresset Asset Management LLC now owns 100,506 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 4,080 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in ImmuCell by 20.1% in the 2nd quarter. Geode Capital Management LLC now owns 45,727 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 7,645 shares in the last quarter. Institutional investors own 13.67% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.